481 related articles for article (PubMed ID: 31306117)
1. Relationships Between Diffusion Tensor Imaging and Cerebrospinal Fluid Metrics in Early Stages of the Alzheimer's Disease Continuum.
Alm KH; Bakker A
J Alzheimers Dis; 2019; 70(4):965-981. PubMed ID: 31306117
[TBL] [Abstract][Full Text] [Related]
2. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis.
Kim WH; Racine AM; Adluru N; Hwang SJ; Blennow K; Zetterberg H; Carlsson CM; Asthana S; Koscik RL; Johnson SC; Bendlin BB; Singh V
Neuroimage Clin; 2019; 21():101586. PubMed ID: 30502079
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
[TBL] [Abstract][Full Text] [Related]
5. Association of Superficial White Matter Alterations with Cerebrospinal Fluid Biomarkers and Cognitive Decline in Neurodegenerative Dementia.
Contarino VE; Siggillino S; Arighi A; Scola E; Fumagalli GG; Conte G; Rotondo E; Galimberti D; Pietroboni AM; Carandini T; Leemans A; Bianchi AM; Triulzi FM
J Alzheimers Dis; 2022; 85(1):431-442. PubMed ID: 34864664
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
7. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
8. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
10. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment.
Selnes P; Aarsland D; Bjørnerud A; Gjerstad L; Wallin A; Hessen E; Reinvang I; Grambaite R; Auning E; Kjærvik VK; Due-Tønnessen P; Stenset V; Fladby T
J Alzheimers Dis; 2013; 33(3):723-36. PubMed ID: 23186987
[TBL] [Abstract][Full Text] [Related]
11. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
13. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
14. CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease.
Bendlin BB; Carlsson CM; Johnson SC; Zetterberg H; Blennow K; Willette AA; Okonkwo OC; Sodhi A; Ries ML; Birdsill AC; Alexander AL; Rowley HA; Puglielli L; Asthana S; Sager MA
PLoS One; 2012; 7(6):e37720. PubMed ID: 22701578
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal Fluid sTREM2 Has Paradoxical Association with Brain Structural Damage Rate in Early- and Late-Stage Alzheimer's Disease.
Leng F; Zhan Z; Sun Y; Liu F; Edison P; Sun Y; Wang Z;
J Alzheimers Dis; 2022; 88(1):117-126. PubMed ID: 35491791
[TBL] [Abstract][Full Text] [Related]
16. CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease.
Walsh P; Sudre CH; Fiford CM; Ryan NS; Lashley T; Frost C; Barnes J;
Neurobiol Aging; 2020 Jul; 91():5-14. PubMed ID: 32305782
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
18. Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment.
Canuet L; Pusil S; López ME; Bajo R; Pineda-Pardo JÁ; Cuesta P; Gálvez G; Gaztelu JM; Lourido D; García-Ribas G; Maestú F
J Neurosci; 2015 Jul; 35(28):10325-30. PubMed ID: 26180207
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid-β42 and White Matter Microstructure in Cognitively Healthy Adults.
Iriondo A; García-Sebastian M; Arrospide A; Arriba M; Aurtenetxe S; Barandiaran M; Clerigue M; Ecay-Torres M; Estanga A; Gabilondo A; Izagirre A; Saldias J; Tainta M; Villanua J; Blennow K; Zetterberg H; Mar J; Abad-García B; Dias IHK; Goñi FM; Martínez-Lage P
J Alzheimers Dis; 2020; 76(2):643-656. PubMed ID: 32538843
[TBL] [Abstract][Full Text] [Related]
20. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
